Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strides' US Revenues Soar As Recovery Strategy Is ‘Executing To Plan’

Executive Summary

Strides Pharma is “very confident” about future after the Indian company’s fourth-quarter US revenues rocketed by 181% and EBITDA margins beat market expectations.

You may also be interested in...



Strides Fast-Tracks China Entry With Joint Venture

India’s Strides has announced its entry into China through a joint-venture with one of the country’s leading pharmaceutical firms, Sihuan, at the same time as reporting first-quarter EBITDA that soared by 155%.

Strides’ Puducherry Plant Gets FDA Warning Letter

India’s Strides has received a warning letter from the US Food and Drug Administration over compliance issues at its Puducherry plant. However, the firm has told investors the regulatory action will not affect its forecast of 20% US sales growth for this financial year.

Strides Builds North American Presence With Acquisitions In US And Canada

While planning to exit its Australian business, Strides Pharma Science has bolstered its presence in North America by gaining full control of its joint venture with Vivimed Labs, along with acquiring Vensun Pharmaceuticals in the US. The Indian firm has also bought a majority stake in Canada’s Pharmapar.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel